StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) International — Organic / Comparable Sales Growth (%) (%)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

Latest, Q3 2026
4.9%
Period ended Sep 30, 2026
Change on a year earlier
-9.8 pts
14.7% in Q3 2025
History
43 quarters
Since Q4 2015
Sources
43
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDiabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) International — Organic / Comparable Sales Growth (%) (%)Year on yearSource
Q3 2026Sep 30, 20264.9%-9.8 ptsSEC Filing (0001628280-26-066601) ↗
Q2 2026Jun 30, 20269.2%-5.5 ptsSEC Filing (0001628280-26-048377) ↗
Q1 2026Mar 31, 20265.7%-9.7 ptsSEC Filing (0001628280-26-025365) ↗
Q4 2025Dec 31, 20259.6%-10.1 ptsSEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 202514.7%-1.8 ptsSEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 202514.7%+1.0 ptsSEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 202515.4%-4.2 ptsSEC Filing (0001628280-25-017924) ↗
Q4 2024Dec 31, 202419.7%+3.5 ptsSEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 202416.5%-5.8 ptsSEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 202413.7%-5.1 ptsSEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 202419.6%–SEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 202316.2%+6.4 ptsSEC Filing (0001628280-24-002009) ↗
Q3 2023Sep 30, 202322.3%+16.8 ptsSEC Filing (0001628280-23-034544) ↗
Q2 2023Jun 30, 202318.8%+6.4 ptsSEC Filing (0001628280-23-025156) ↗
Q4 2022Dec 31, 20229.8%-14.5 ptsSEC Filing (0001628280-23-001516) ↗
Q3 2022Sep 30, 20225.5%-20.5 ptsSEC Filing (0001628280-22-026588) ↗

Cite this data

StockData. (2026). Abbott Laboratories Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) International — Organic / Comparable Sales Growth (%) (%), quarterly Q4 2015–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-dc-yoy-org-intl

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.